These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 3105134)

  • 1. Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation.
    Goldstein G
    Transplant Proc; 1987 Apr; 19(2 Suppl 1):1-6. PubMed ID: 3105134
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunologic monitoring of Orthoclone OKT3-treated patients: the problem of antimonoclonal immune response.
    Bach JF; Chatenoud L
    Transplant Proc; 1987 Apr; 19(2 Suppl 1):17-20. PubMed ID: 3105135
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunologic monitoring with Orthoclone OKT3 therapy.
    Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB
    J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical development of Orthoclone OKT3.
    Cosimi AB
    Transplant Proc; 1987 Apr; 19(2 Suppl 1):7-16. PubMed ID: 3105142
    [No Abstract]   [Full Text] [Related]  

  • 5. A U.S. clinical study of Orthoclone OKT3 in renal transplantation.
    Norman DJ; Shield CF; Barry J; Henell K; Funnell MB; Lemon J
    Transplant Proc; 1987 Apr; 19(2 Suppl 1):21-7. PubMed ID: 3105136
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of Orthoclone OKT3 monoclonal antibody to reverse acute renal allograft rejection unresponsive to treatment with conventional immunosuppressive regimens.
    Monaco A; Goldstein G; Barnes L
    Transplant Proc; 1987 Apr; 19(2 Suppl 1):28-31. PubMed ID: 3105137
    [No Abstract]   [Full Text] [Related]  

  • 7. Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression.
    Jaffers GJ; Fuller TC; Cosimi AB; Russell PS; Winn HJ; Colvin RB
    Transplantation; 1986 May; 41(5):572-8. PubMed ID: 3085297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimurine antibody to OKT3 in cardiac transplantation: implications for prophylaxis and retreatment of rejection.
    O'Connell JB; Bristow MR; Hammond EH; Menlove RL; Ensley RD; Ratkovec RM; Renlund DG
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1157-9. PubMed ID: 1899154
    [No Abstract]   [Full Text] [Related]  

  • 9. Review and preview of anti-T-cell antibodies.
    Helderman JH
    Transplant Proc; 1995 Oct; 27(5 Suppl 1):8-9. PubMed ID: 7482824
    [No Abstract]   [Full Text] [Related]  

  • 10. In situ antigenic modulation of human graft-infiltrating T cells is induced by OKT3 treatment.
    Caillat-Zucman S; Legendre C; Noel LH; Bach JF; Kreis H; Chatenoud L
    Transplant Proc; 1990 Aug; 22(4):1782. PubMed ID: 2143860
    [No Abstract]   [Full Text] [Related]  

  • 11. First and second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection followed by testing for anti-OKT3 IgM and/or IgG immunization.
    Birkeland SA; Bach JF; Chatenoud L; Jørgensen KA; Strate M; Elbirk A; Rohr N; Svendsen V
    Transplant Proc; 1990 Feb; 22(1):221-2. PubMed ID: 2106740
    [No Abstract]   [Full Text] [Related]  

  • 12. Orthoclone OKT3 monoclonal antibody reversal of hepatic and cardiac allograft rejection unresponsive to conventional immunosuppressive treatments.
    Kremer AB; Barnes L; Hirsch RL; Goldstein G
    Transplant Proc; 1987 Apr; 19(2 Suppl 1):54-7. PubMed ID: 3105141
    [No Abstract]   [Full Text] [Related]  

  • 13. Prolonged and repeated courses of OKT3 after liver transplantation.
    Colledan M; Gridelli B; Rossi G; Caccamo L; Gatti S; Bonara P; Fassati LR; Ferla G; Maggi U; Reggiani P
    Transplant Proc; 1990 Aug; 22(4):1769-71. PubMed ID: 2143859
    [No Abstract]   [Full Text] [Related]  

  • 14. OKT3 for induction immunosuppression in renal transplantation: a comparative study of high versus low doses.
    Norman DJ; Barry JM; Bennett WM; Munson JL; Meyer M; Henell K; Kimball J; Hubert B
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1052-4. PubMed ID: 1846453
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapeutic use of the OKT3 anti-T cell monoclonal antibody: mode of action and side effects.
    Chatenoud L
    Transplant Proc; 1988 Oct; 20(5 Suppl 6):79-83. PubMed ID: 3140452
    [No Abstract]   [Full Text] [Related]  

  • 16. The use of OKT3 to treat steroid-resistant renal allograft rejection in patients receiving cyclosporine.
    Thistlethwaite JR; Haag BW; Gaber AO; Stuart JK; Aronson AJ; Mayes JT; Lloyd DM; Stuart FP
    Transplant Proc; 1987 Feb; 19(1 Pt 3):1901-4. PubMed ID: 3103294
    [No Abstract]   [Full Text] [Related]  

  • 17. OKT3 resistant rejection in liver transplant patients.
    Sutherland F; Lazarovits A; Aboujaoude M; Grant D; Ghent C; Sommerauer J; Wall W
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1413-4. PubMed ID: 1824898
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of Orthoclone OKT3 monoclonal antibody in cardiac transplantation: early experience with rejection prophylaxis and treatment of refractory rejection.
    Gilbert EM; Eiswirth CC; Renlund DG; Menlove RL; DeWitt CW; Freedman LA; Herrick CM; Gay WA; Bristow MR
    Transplant Proc; 1987 Apr; 19(2 Suppl 1):45-53. PubMed ID: 3105140
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunologic monitoring in OKT3-treated kidney graft recipients.
    Zlabinger GJ; Maurer D; Ulrich W; Meron G; Pohanka E; Kovarik J
    Transplant Proc; 1990 Aug; 22(4):1777-8. PubMed ID: 2117807
    [No Abstract]   [Full Text] [Related]  

  • 20. Monoclonal antibody OKT3 in cardiac and renal transplantation.
    Norman DJ
    Bibl Cardiol; 1988; (43):27-32. PubMed ID: 3147656
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.